Penny stocks are some of the most active and volatile types of stocks in the stock market today. But what everyone knows about these is that they can break out in a big way. That’s why so many continue to look for the best penny stocks to buy.
In this regard, several economic and sector events have sparked interest in a number of small-cap and micro-cap stocks this week. Here is a list of 4 penny stocks that may be worth watching this week:
Penny Stocks To Watch #1: PharmaCyte Biotech (PMCB)
There has been no lack of attention on biotech penny stocks this year. At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes.
The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods. For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.
On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.
Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.
Penny Stocks To Watch #2: Discovery Gold (DCGD)
One of the more volatile penny stocks to watch this month has been Discovery Gold (DCGD Stock Report). Though the stock is not mining, it is participating in another industry that has seen its own “rush:” cannabis. For the better part of the last quarter, shares of Discovery Gold have climbed from $0.01 to as high as $2.22. Over the last few days, however, the marijuana stock took an aggressive tumble to lows of $0.43.
The company had previously announced that it would be pursuing a name change to GRN Holdings Corporation. Over the past few months, GRN has been adding new management and advisory members. Most of them have some background in the cannabis industry.
On Monday, DCGD shares saw a dramatic trend reversal compared to its previous two trading sessions. Shares opened the week at $0.64 and have seen highs of $0.81 heading into the lunch hour on Monday. The company hosted web conferences on the 13th, throughout the afternoon.
Penny Stocks To Watch #3: Fannie Mae (FNMA)
One of the more popular housing penny stocks to watch this month has been Fannie Mae (FNMA Stock Report). Thanks to the government’s focus on overhauling the company, the market has been monitoring progress closely. The mortgage giant, along with Freddie Mac, has seen a rise in price from lows this month of $2.51 to highs of $3.98 during the early lunch hour on Monday. Since the beginning of the year, FNMA stock has risen by as much as 272%.
The firm announced the results of its thirteenth reperforming loan sale transaction. The deal, which was announced on August 13, 2019, included the sale of approximately 29,400 loans totaling $5.1 billion in unpaid principal balance (UPB), divided into six pools. The winning bidders of the six pools for the transaction were Goldman Sachs Mortgage Company (Goldman Sachs) for Pool 1, Towd Point Master Funding LLC (Cerberus) for Pools 2, 3, 4, NRZ Mortgage Holdings, LLC (Fortress) for Pool 5, and DLJ Mortgage Capital, Inc. (Credit Suisse) for Pool 6. The transaction is expected to close on October 25, 2019.
Penny Stocks To Watch #4: Cardiff Lexington Corporation (CDIX)
The last penny stock to watch on this list is Cardiff Lexington Corporation (CDIX Stock Report). Shares of the sub-penny stock have climbed from lows of $0.0014 on September 10 to highs of $0.0059 as of the 12 o’clock hour on Monday. This move of more than 320% came as the company is in the midst of several key developments.
First, Cardiff announced in late August that, along with Acela BioMedical, LLC, the two have signed a Letter of Intent whereby Acela BioMedical would become a subsidiary of Cardiff Lexington. Acela Biomedical is an existing Hemp grower, distributor, processor, extractor, and retailor specializing in CBD Oil Production with over two million plants in the ground in Kentucky. Its processing facility is currently in operation.
In addition to this, Cardiff announced this month that the Company has received $410,000.00 in new funding from the Private Equity Group, Leonite Capital, LLC. As a result, Cardiff was able to pay off three significant convertible notes totaling $379,902 and further, plans to retire all commercial notes by year-end 2019 in concert with acquisition-related equity funding.
3 Penny Stocks Looking To Change The Biotech Industry
The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.
Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.
GT Biopharma Inc. (GTBP)
One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.
So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.
One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.
“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.
Conatus Pharmaceuticals Inc. (CNAT)
This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.
In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.
Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.
Nuvectra Corporation (NVTR)
To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.
Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.
Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here
Are These Biotech Names On Your October Watch List?
Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.
Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.
Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)
The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.
The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.
Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.
Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)
The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.
The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.
Stock Price Newsletter – October 18, 2019
Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch
The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.
In Case You Missed It: Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient
Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.
These Healthcare & Biotech Stocks Deserve Your Attention This Month
The positive results provided a break for the sector. Furthermore, healthcare stocks have risen by 5.7% this year. The entire index has seen a nearly 20 percent gain, according to The Wall Street Journal. With this in mind, healthcare and biotechnology stocks are in focus this month.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured5 days ago
What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!
Biotechnology2 weeks ago
Biotech Stocks In Focus Amid New Wave Of Drug Delivery
Biotechnology1 week ago
3 Top Biotech Stocks To Monitor In October
Biotechnology4 days ago
Healthcare Stocks To Watch Amid Bullish Earnings
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch After Latest News
Biotechnology3 days ago
Biotech Stocks To As Sector ETF’s Climb Higher
Biotechnology1 week ago
Biotechnology Stocks Gaining Ground In October; What To Watch
Biotechnology2 weeks ago
Top Healthcare Stocks To Watch On Tuesday Morning